



OMIDRIA[®]
(phenylephrine and ketorolac
intraocular solution)
1% / 0.3%



OMIDRIA STORAGE AND PREPARATION REQUIREMENTS

The following information is provided to help integrate OMIDRIA into your operating routine.

OMIDRIA dilution and storage¹



Prior to dilution

- Store at 20°C to 25°C (68°F to 77°F)
- Protect from light



Easy to integrate into routine operating procedures

- Add preoperatively to irrigation solution
- Do not use if the solution is cloudy or contains particulate matter.




After dilution, product can be stored:

- Up to 4 hours at room temperature
- Up to 24 hours if refrigerated



Preparation and administration of OMIDRIA¹

- Add preoperatively to irrigation solution
 - One 4-mL single-patient-use vial to 500-mL ophthalmic irrigating solution
 - No other preparation required
 - Can be added to irrigation solution in the surgical suite
 - No calculations—preparation is the same for every patient
- Additionally, you may place an OMIDRIA container sticker, which is available from your OMIDRIA sales representative, on the container of diluted irrigating solution



OMIDRIA[®]
(phenylephrine and ketorolac
intraocular solution)
1% / 0.3%

Name: _____

DOB: _____ **Eye:** OS (Left) OD (Right)

2018-054

INDICATIONS AND USAGE

OMIDRIA[®] is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

IMPORTANT SAFETY INFORMATION

OMIDRIA must be added to irrigating solution prior to intraocular use.

OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.

Systemic exposure to phenylephrine may cause elevations in blood pressure.

Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.

Please see additional Important Safety Information on reverse, and the Full Prescribing Information for OMIDRIA at www.omidriahcp.com/prescribinginformation.



OMIDRIA SETS THE STAGE FOR YOUR CATARACT SURGERY SUCCESS¹⁻³

FDA-approved OMIDRIA: Count on performance that stays ahead of the unexpected

-  **EFFECTIVELY MAINTAINS PUPIL DILATION** and requires less use of PEDs^{1,4-8}
-  **REDUCES COMPLICATIONS** such as IFIS, CME, and breakthrough iritis^{2,3}
-  **IMPROVED PATIENT EXPERIENCE** with less pain, greater visual acuity, and fewer drops^{1,3,4}

CME=cystoid macular edema; IFIS=intraoperative floppy iris syndrome; PEDs=pupil expansion devices.

Dedicated access and support for your patients



OMIDRIA is covered and paid by **100% of Medicare Administrative Contractors (MACs)** in the ambulatory surgery center (ASC) setting across all **50 states** and Puerto Rico.⁹

OMIDRIA has a unique billing code: **J1097**
Phenylephrine 10.16 mg/mL and ketorolac 2.88 mg/mL ophthalmic irrigation solution, 1 mL¹⁰

OMIDRIA is reimbursed per mL; therefore, providers should always use **1 mL** as the billing unit and bill for 4 units when OMIDRIA is utilized.

Non-opioid OMIDRIA qualifies for separate payment by the Centers for Medicare & Medicaid Services (CMS) when used in ASCs.¹¹

IMPORTANT SAFETY INFORMATION (CONTINUED)

The most commonly reported adverse reactions at $\geq 2\%$ are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Please see the Full Prescribing Information for OMIDRIA at www.omidriahcp.com/prescribinginformation.

You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

For more information about OMIDRIA, please call 1-877-OMIDRIA (1-877-664-3742), visit www.omidriahcp.com, or scan the QR code.



References: 1. OMIDRIA [package insert]. Seattle, WA: Omeros Corporation; 2017. 2. Silverstein SM, Rana VK, Stephens R, et al. Effect of phenylephrine 1.0%-ketorolac 0.3% injection on tamsulosin-associated intraoperative floppy-iris syndrome. *J Cataract Refract Surg.* 2018;44(9):1103-1108. 3. Visco DM, Bedi R. Effect of intracameral phenylephrine 1.0%-ketorolac 0.3% on postoperative cystoid macular edema, iritis, pain, and photophobia after cataract surgery. *J Cataract Refract Surg.* 2020;46(6):867-872. 4. Rosenberg ED, Nattis AS, Alevi D, et al. Visual outcomes, efficacy, and surgical complications associated with intracameral phenylephrine 1.0%/ketorolac 0.3% administered during cataract surgery. *Clin Ophthalmol.* 2018;12:21-28. 5. Al-Hashimi S, Donaldson K, Davidson R, et al. Medical and surgical management of the small pupil during cataract surgery. *J Cataract Refract Surg.* 2018;44(8):1032-1041. 6. Bucci FA Jr, Michalek B, Fluet AT. Comparison of the frequency of use of a pupil expansion device with and without an intracameral phenylephrine and ketorolac injection 1%/0.3% at the time of routine cataract surgery. *Clin Ophthalmol.* 2017;11:1039-1043. 7. Walter K, Delwadia N, Coben J. Continuous intracameral phenylephrine-ketorolac irrigation for miosis prevention in femtosecond laser-assisted cataract surgery: reduction in surgical time and iris manipulation. *J Cataract Refract Surg.* 2019;45(4):465-469. 8. Visco D. Effect of phenylephrine/ketorolac on iris fixation ring use and surgical times in patients at risk of intraoperative miosis. *Clin Ophthalmol.* 2018;12:301-305. 9. Centers for Medicare & Medicaid Services. ASC Payment Rates – Addenda. Updated February 10, 2022. Accessed March 10, 2022. <https://www.cms.gov/license/ama?file=/files/zip/january-2022-asc-approved-hcpcs-code-and-payment-rates-updated-02102022.zip> 10. Centers for Medicare & Medicaid Services. HCPCS April 2022 Index. Accessed March 10, 2022. <https://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/HCPCS-Quarterly-Update> 11. US Department of Health and Human Services. Medicare program: hospital outpatient prospective payment and ambulatory surgical center payment systems and quality reporting programs; price transparency of hospital standard charges; radiation oncology model; request for information on rural emergency hospitals. *Fed Regist.* 2021;86(147):42018-42360.



Rayner, the Rayner logo, OMIDRIA, and the OMIDRIA logo are proprietary marks of Rayner.

© 2022 Rayner Surgical Inc. or its affiliates, all rights reserved. EC 2022-34 US 03/22



OMIDRIA[®]

(phenylephrine and ketorolac
intraocular solution)
1% / 0.3%